<DOC>
	<DOCNO>NCT00881036</DOCNO>
	<brief_summary>Individuals resolve hepatitis B , characterize hepatitis B surface antigen ( HBsAg ) -negative hepatitis B core antibody-positive , latent hepatitis B virus ( HBV ) infection liver tissue . Cytotoxic chemotherapy hematopoietic stem cell transplantation sometimes trigger reactivation latently infect HBV , result de novo hepatitis B . Although de novo hepatitis B could cause acute liver failure chronic hepatitis , effective management strategy de novo hepatitis B well established . Risk factor effective management de novo hepatitis B clarify .</brief_summary>
	<brief_title>Activation Hepatitis B Virus ( HBV ) Hepatitis B Surface Antigen ( HBsAg ) - Negative But Hepatitis B Core Antibody ( Anti-HBc ) - Positive Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<criteria>HBsAgnegative antiHBcpositive Serum HBV DNAnegative</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Hepatitis B</keyword>
</DOC>